-
Something wrong with this record ?
Targeting ERK-Hippo Interplay in Cancer Therapy
K. Vališ, P. Novák
Language English Country Switzerland
Document type Journal Article, Review
Grant support
ERA-Net for Research Programmes on Rare Diseases, project ReCognitION
Ministerstvo Školství, Mládeže a Tělovýchovy
RVO61388971
Akademie Věd České Republiky
LQ1604
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
Free Medical Journals
from 2000
Freely Accessible Science Journals
from 2000
PubMed Central
from 2007
Europe PubMed Central
from 2007
ProQuest Central
from 2000-03-01
Open Access Digital Library
from 2000-01-01
Open Access Digital Library
from 2007-01-01
Health & Medicine (ProQuest)
from 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
from 2000
PubMed
32375238
DOI
10.3390/ijms21093236
Knihovny.cz E-resources
- MeSH
- Extracellular Signal-Regulated MAP Kinases antagonists & inhibitors metabolism MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Humans MeSH
- Neoplasms drug therapy metabolism MeSH
- Protein Serine-Threonine Kinases antagonists & inhibitors metabolism MeSH
- Antineoplastic Agents therapeutic use MeSH
- Signal Transduction MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Extracellular signal-regulated kinase (ERK) is a part of the mitogen-activated protein kinase (MAPK) signaling pathway which allows the transduction of various cellular signals to final effectors and regulation of elementary cellular processes. Deregulation of the MAPK signaling occurs under many pathological conditions including neurodegenerative disorders, metabolic syndromes and cancers. Targeted inhibition of individual kinases of the MAPK signaling pathway using synthetic compounds represents a promising way to effective anti-cancer therapy. Cross-talk of the MAPK signaling pathway with other proteins and signaling pathways have a crucial impact on clinical outcomes of targeted therapies and plays important role during development of drug resistance in cancers. We discuss cross-talk of the MAPK/ERK signaling pathway with other signaling pathways, in particular interplay with the Hippo/MST pathway. We demonstrate the mechanism of cell death induction shared between MAPK/ERK and Hippo/MST signaling pathways and discuss the potential of combination targeting of these pathways in the development of more effective anti-cancer therapies.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012617
- 003
- CZ-PrNML
- 005
- 20210507102550.0
- 007
- ta
- 008
- 210420s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms21093236 $2 doi
- 035 __
- $a (PubMed)32375238
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Vališ, Karel $u Laboratory of Structural Biology and Cell Signaling, Institute of Microbiology of the Czech Academy of Sciences, 14220 Prague, Czech Republic
- 245 10
- $a Targeting ERK-Hippo Interplay in Cancer Therapy / $c K. Vališ, P. Novák
- 520 9_
- $a Extracellular signal-regulated kinase (ERK) is a part of the mitogen-activated protein kinase (MAPK) signaling pathway which allows the transduction of various cellular signals to final effectors and regulation of elementary cellular processes. Deregulation of the MAPK signaling occurs under many pathological conditions including neurodegenerative disorders, metabolic syndromes and cancers. Targeted inhibition of individual kinases of the MAPK signaling pathway using synthetic compounds represents a promising way to effective anti-cancer therapy. Cross-talk of the MAPK signaling pathway with other proteins and signaling pathways have a crucial impact on clinical outcomes of targeted therapies and plays important role during development of drug resistance in cancers. We discuss cross-talk of the MAPK/ERK signaling pathway with other signaling pathways, in particular interplay with the Hippo/MST pathway. We demonstrate the mechanism of cell death induction shared between MAPK/ERK and Hippo/MST signaling pathways and discuss the potential of combination targeting of these pathways in the development of more effective anti-cancer therapies.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a extracelulárním signálem regulované MAP kinasy $x antagonisté a inhibitory $x metabolismus $7 D048049
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory $x farmakoterapie $x metabolismus $7 D009369
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a protein-serin-threoninkinasy $x antagonisté a inhibitory $x metabolismus $7 D017346
- 650 _2
- $a signální transdukce $7 D015398
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Novák, Petr $u Laboratory of Structural Biology and Cell Signaling, Institute of Microbiology of the Czech Academy of Sciences, 14220 Prague, Czech Republic
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 9 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32375238 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507102549 $b ABA008
- 999 __
- $a ok $b bmc $g 1650890 $s 1132996
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 21 $c 9 $e 20200503 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a ERA-Net for Research Programmes on Rare Diseases, project ReCognitION $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a RVO61388971 $p Akademie Věd České Republiky
- GRA __
- $a LQ1604 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20210420